Merck + Co., Inc.

Marvin M Goldenberg

Philippe L Durette

Timothy Francis Gallagher

Bruce E Witzel

Kathleen M Rupprecht

Debra L Allison

Allan N Tischler

Doris L Keller

Method for increasing resistance to gastro-intestinal irritation, and for the treatment of pain, fever, inflammation, arthritic conditions, asthma, allergic disorders, skin diseases, cardiovascular disorders, psoriasis, inflammatory bowel disease, glaucoma or other prostaglandin and/or leukotriene mediated diseases comprising the administration to a subject in need of such treatment, a non-toxic therapeutically effective amount of compound of formula I: ##STR1##

N-alkenyl-3-hydroxybenzo[b]thiophene-2-carboxamide derivatives as dual

N-Alkenyl-3-hydroxybenzo[b]thiophene-2-carboxamide derivatives have been prepared by:

Combinations of cyclo-(N-methyl-Ala-Tyr-D-Trp-Lys-Val-Phe) and a NSAID have been found to exhibit much lower gastric lesions or ulcers than normally associated with NSAIDs and are thereby clinically useful in long-term therapy for patients suffering from chronic rheumatoid arthritis or osteoarthritis.

Anti-inflammatory/analgesic combination of

The somatostatin analog L-363,586 is a cyclic hexapeptide having the structure; cyclo-(N-methyl-Ala-Tyr-d-Trp-Lys-Val-Phe). L-363,586 has been found to be useful for inducing gastric cytoprotection via a mechanism not involving the inhibition of gastric acid secretions. Specific therapeutic utilities include, erosive gastritis, erosive esophagitis, inflammatory bowel disease and ethanol induced hemorrhagic gastric erosions.

Gastric cytoprotection with L-363,586

Combinations of .alpha.-fluoromethylhistidine and a NSAID have been found to exhibit higher efficacy and shorter onset of action in the treatment of pain and inflammation.

Growing community of inventors

Westfield, NJ, United States of America

Marvin M Goldenberg